Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.64 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 3/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26255822 | 1.00 | GLP1R (0.64) | GLP1RLPAR3LPAR1NOD1FAAH | |
| SCHEMBL23475913 | 0.98 | GLP1R (0.62) | GLP1RLPAR3LPAR1NOD1FAAH | |
| SCHEMBL18202629 | 0.98 | GLP1R (0.62) | GLP1RLPAR3LPAR1NOD1FAAH | |
| SCHEMBL23475930 | 0.98 | GLP1R (0.62) | GLP1RLPAR3LPAR1NOD1FAAH | |
| SCHEMBL27436033 | 0.98 | GLP1R (0.62) | GLP1RLPAR3LPAR1NOD1FAAH | |
| SCHEMBL26257014 | 0.92 | GLP1R (0.58) | GLP1RLPAR3LPAR1NOD1FAAH | |
| SCHEMBL23475890 | 0.90 | GLP1R (0.57) | GLP1RNOD1SIRT2 | |
| SCHEMBL18186925 | 0.90 | GLP1R (0.57) | GLP1RNOD1SIRT2 | |
| SCHEMBL23475979 | 0.90 | GLP1R (0.57) | GLP1RNOD1SIRT2 | |
| SCHEMBL16830716 | 0.90 | GLP1R (0.57) | GLP1RNOD1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367259-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2025-12-04 | — | — | US | disclosed |
| US-12337028-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-11865160-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4212180-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | The Scripps Research Institute (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220000981-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-06 | — | — | US | disclosed |
| US-20220000981-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-06 | — | — | US | disclosed |
| US-11007252-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007252-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-05-18 | — | — | US | disclosed |
| US-20180344812-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2018-12-06 | — | — | US | disclosed |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10010589-B2 | — | — | 2018-07-03 | — | — | US | disclosed |
| US-10010589-B2 | — | — | 2018-07-03 | — | — | US | disclosed |
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-11-03 | — | — | US | disclosed |
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-11-03 | — | — | US | disclosed |
| WO-2015095406-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344812-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885LPAR3 393/4885LPAR1 348/4885 |
| US-12337028-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885LPAR3 393/4885LPAR1 348/4885 |
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885LPAR3 393/4885LPAR1 348/4885 |
| US-20220000981-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885LPAR3 393/4885LPAR1 348/4885 |
| US-11007252-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885LPAR3 393/4885LPAR1 348/4885 |
| US-10010589-B2 | — | TYMP, MTAP, TUBB6 | GLP1R 3915/4885LPAR3 1742/4885LPAR1 1806/4885 |
| US-20250367259-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | GLP1R 411/4885LPAR3 393/4885LPAR1 354/4885 |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885LPAR3 393/4885LPAR1 348/4885 |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885LPAR3 393/4885LPAR1 348/4885 |
| US-11865160-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885LPAR3 393/4885LPAR1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.